Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Oatly Group AB - ADR — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Oatly Group AB - ADR trades at $11.1 (market cap $347.84M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 2.8× Oatly Group AB - ADR's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Oatly Group AB - ADR for 18 Days on average.
| MRVI | OTLY | |
|---|---|---|
Market Cap | $972.90M | $347.84M |
Volume | 4,325,710 | 116,933 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $15.91 |
52-Week Low | $2.83 | $8.03 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $1.08B | $852.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
OTLY trades at $11.15, up 4.5% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $862M in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Recent Q2 2026 results beat expectations and management raised full-year revenue guidance, driving positive sentiment.
While OTLY demonstrates operational progress with margin improvement and revenue acceleration, significant risks remain including persistent losses, high debt levels, and negative cash flow. Analyst consensus is mixed with 44% buy ratings but a modest $12.28 price target suggesting limited upside from current levels amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
